Inhibition of Transcriptional Regulator Taz (Wwtr1) by Antisense Oligonucleotide (ASO) Treatment Improves Obesity and Hepatic Steatosis in a Mouse Model of NASH
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-2439-pub
Abstract: Nonalcoholic fatty liver disease (NAFLD) is a common disorder that affects millions of people around the world. People with fatty liver disease alone are usually asymptomatic until a second insult to the liver, such as… read more here.
Keywords: aso treatment; taz; ionis pharmaceuticals; pharmaceuticals inc ... See more keywords